foxo4-dri senolytic 2024 animal model Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Peptide inhibitors targeting FOXO4-p53 interactions
Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging: Cell PDF) The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data
Pay in 4 interest-free payments of $5.98 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7




